目的 探討培美曲塞聯(lián)合順鉑治療宮頸癌的臨床療效和安全性。方法 選擇2010年2月-2014年2月遼寧省腫瘤醫(yī)院收治的宮頸癌患者100例,隨機(jī)分為對照組和治療組,每組50例。對照組患者在每個化療療程的第一天使用注射用順鉑50 mg/m²加入250 mL生理鹽水中靜脈滴注,時間大于2 h。治療組患者在第一天使用注射用培美曲塞二鈉500 mg/m²加入250 mL生理鹽水中靜脈滴注,時間大于10 min。培美曲塞滴注結(jié)束后30 min開始滴注注射用順鉑,用法用量同對照組。兩組均以21 d為1個化療療程,至少進(jìn)行4個療程的化療。評價兩組患者的臨床療效和毒副反應(yīng)。結(jié)果 治療后,對照組總有效率為24.0%,臨床獲益率為52.0%;治療組總有效率為44.0%,臨床獲益率為74.0%,兩組患者總有效率、臨床獲益率比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療過程中,兩組患者均可發(fā)生白細(xì)胞減少、紅細(xì)胞減少、中性粒細(xì)胞減少、惡心、嘔吐、腹瀉、發(fā)熱、口腔黏膜炎等不良反應(yīng),且治療組的發(fā)生率顯著低于對照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。治療組的無進(jìn)展生存期(PFS)和總生存時間(OS)分別平均為5.2個月和10.3個月,對照組分別為3.8個月和9.7個月,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 培美曲塞聯(lián)合順鉑治療宮頸癌具有較好的臨床療效,可降低化療的不良反應(yīng),值得臨床推廣應(yīng)用。

Objective To investigate the efficacy and safety of pemetrexed combined with cisplatin in treatment of cervical cancer. Methods Patients (100 cases) with cervical cancer who came to Liaoning Cancer Hospital from February 2010 to February 2014 were randomly divided into the control and treatment groups, and each group had 50 cases. The patients in the control group were iv administered with Cisplatin for injection (50 mg/m² diluted with 250 mL physiological saline) more than 2 h on the first day. The patients in the treatment group were iv administered with Pemetrexed Disodium for injection (500 mg/m² diluted with 250 mL physiological saline) more than 10 min. And they were given Cisplatin for injection when pemetrexed dripped 30 min later, while the usage and dosage of Cisplatin for injection were same with control group. One course of treatment was 21 D, and two groups were treated for at least four courses of chemotherapy. The clinical curative effect and adverse reaction in two groups were evaluated. Results After treatment, the total effective rate of control group was 24.0%, and the clinical benefit rate was 52.0%, while the total effective rate of treatment group was 44.0%, and the clinical benefit rate was 74.0%, and there were differences between two groups (P< 0.05). Adverse reactions such as reducing of white blood cells, red blood cells, and neutropenia, nausea, vomiting, diarrhea, fever, inflammation of oral mucosa can happen in two groups during the course of the treatment, and the incidence rate of treatment group was significantly lower than that of the control group, and there were differences between two groups (P< 0.05). The progression-free survival (PFS) and overall survival (OS) in treatment group were 5.2 months and 10.3 months, respectively, while those in the control group were 3.8 months and 9.7 months, and there were differences between two groups (P< 0.05). Conclusion Pemetrexed combined with cisplatin has the good clinical effect in treatment of cervical cancer, and can reduce the adverse reaction of chemotherapy, which is worth clinical promotion.